RET融合肺癌的特征及诊疗进展  

A comprehensive overview of RET fusion lung caner’s characters,diagnosis and treatment

作　　者：马千里[1] 张瑾[1] 鲍彤[1] 田周俊逸 梁朝阳[1] 刘德若[1] Ma Qianli;Zhang Jin;Bao Tong;Tianzhou Junyi;Liang Chaoyang;Liu Deruo(Department of Thoracic Surgery,China Japan Friendship Hospital,Beijing 100029,China)

机构地区：[1]中日友好医院胸外科,北京100029

出　　处：《中华胸心血管外科杂志》2022年第5期305-309,共5页Chinese Journal of Thoracic and Cardiovascular Surgery

基　　金：北京市科技计划(Z191100006619008);中日友好医院"菁英计划"人才培育工程(ZRJY2021-GGO2)。

摘　　要：作为新型靶点的RET基因近两年打破了治疗僵局,靶向药物不断获批并快速纳入治疗指南,为非小细胞肺癌患者的生存带来了更多的希望。而RET基因出现一些有驱动细胞癌变的融合变异才被认为是原癌基因,本文综述了RET基因的生物学特性、肺癌中RET融合的分类以及RET融合的检测方法;并进一步讨论RET融合肺癌的病理及临床特征,RET融合肺癌的药物治疗,以及RET融合对耐药和预后的提示作用。The RET(REarranged during transfection)gene as a novel has broken the therapeutic deadlock in the last two years,whith is attributed to the rapid approval of targeted therapies and inclusion in treatment guidelines,bringing more hope for the survival of patients with non-small cell lung cancer(NSCLC).Usually,the main activation of the RET proto-oncogene contributes to the development of lung cancer via somatic rearrangements.Thus,this study reviews the biological characteristics of RET gene,the classification of RET fusion in lung cancer and the detection of RET fusion.Meanwhile the pathological and clinical features,targeted therapies,drug resistance,prognosis of lung cancer patients with RET fusion were further discussed.

关 键 词：RET基因 治疗指南 诊疗进展 细胞癌变 原癌基因 靶向药物 药物治疗 临床特征 

分 类 号：R734.2[医药卫生—肿瘤]